Brian Olshansky

Dept of Cardiac Electrophysiology, University of Iowa Hospitals, USA

Brian Olshansky is tenured Professor of Medicine and Director of Cardiac Electrophysiology at the University of Iowa Hospitals. He directs the Clinical Cardiac Electophysiology Fellowship Training Program.He is recognized for work regarding arrhythmia mechanisms, treatment of atrial and ventricular arrhythmias and evaluation of syncope. His diverse interests range from technological and mechanistic aspects of cardiac electrophysiology to holistic and ethical issues. Professor Olshansky is presently the Principal Investigator and originator of the INTRINSIC RV trial and is involved with magnetic based technologies regarding catheter and lead positioning. He has expertise in the evaluation and treatment of cardiac arrhythmias using state-of-the-art techniques including: device implantation (pacemakers and implanted defibrillators), catheter ablation techniques, including for atrial fibrillation and ventricular tachycardia. He is an internationally known expert in his field and has pursued many avenues of research.

Any competing interests declared are displayed with individual evaluations.

: Cardiovascular Disorders > Arrhythmias, Electrophysiology & Pacing (09 November 2005 - 15 March 2010)

All recent recommendations

• 3.0
  Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy.
  Recommended by Brian Olshansky with Milena Gebska, James Martins
  
• 5.0
  Biventricular pacing in patients with bradycardia and normal ejection fraction.
  Recommended by Brian Olshansky with Rakesh Gopinathannair, Thorsten Lewalter, Carolyn Lam with Jennifer E Ho, Wolfgang Schoels
  
• 8.8
  Cardiac-resynchronization therapy for the prevention of heart-failure events.
  Recommended by Brian Olshansky with Renee M Sullivan, Ole-A Breithardt, I Eli Ovsyshcher with Guy Amit, Johnson Francis with Frijo Jose, Hector Ventura with Anil Verma, Panos Vardas with Dimitris A Arfanakis
  
• 12.4
  Dabigatran versus warfarin in patients with atrial fibrillation.
  Recommended by Robert Ruff, Brian Olshansky with Rakesh Gopinathannair, Luis Ruilope with José A García Donaire, Wilbert Aronow, Fred Weaver with Sung Ham, Philip Gorelick with Fernando Testai, I Eli Ovsyshcher with Guy Amit, Chim Lang with Anna Maria Choy, Heather Bloom, Harri Jenkins, Wolfgang Schoels, Ashfaq Shuaib, Carlos Kase with Aleksandra Pikula , Megan Leary with Angela Adams, Jeffrey Veluz
  
• 6.0
  Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block.
  Recommended by Brian Olshansky with Rakesh Gopinathannair
  
• 6.0
  Do abandoned leads pose risk to implantable cardioverter-defibrillator patients?
  Recommended by Brian Olshansky with Rakesh Gopinathannair
  
• 6.0
  Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study.
  Recommended by Brian Olshansky with Rakesh Gopinathannair
  
• 9.0
  Effect of dronedarone on cardiovascular events in atrial fibrillation.
  Recommended by Brian Olshansky with Rakesh Gopinathannair
  
• 4.8
  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial.
  Recommended by Chim Lang, Brian Olshansky with Rakesh Gopinathannair
  
• 6.6
  Prognostic importance of defibrillator shocks in patients with heart failure.
  Recommended by Hector Ventura, Brian Olshansky with Rakesh Gopinathannair, Melvin Cheitlin
  
• 4.8
  Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1.
  Recommended by Brian Olshansky with Rakesh Gopinathannair, Richard Moxley III with Chad Heatwole
  
• 3.0
  Increased mortality after dronedarone therapy for severe heart failure.
  Recommended by Brian Olshansky with Rakesh Gopinathannair
  
• 10.0
  Rhythm control versus rate control for atrial fibrillation and heart failure.
  Recommended by Brian Olshansky with Chirag Sandesara, Wilbert Aronow, Hector Ventura with Anil Verma, Wolfgang Schoels
  
• 6.0
  Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
  Recommended by Brian Olshansky with Chirag Sandesara
  
• 6.0
  Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death.
  Recommended by Brian Olshansky
  
• 3.0
  Long-term efficacy of catheter ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy.
  Recommended by Brian Olshansky
  
• 3.0
  Ventricular arrhythmias during Tako-tsubo syndrome.
  Recommended by Brian Olshansky
  
• 6.0
  Resting heart rate in cardiovascular disease.
  Recommended by Brian Olshansky
  
• 3.0
  Bradycardia pacing-induced short-long-short sequences at the onset of ventricular tachyarrhythmias: a possible mechanism of proarrhythmia?
  Recommended by Brian Olshansky
  
• 3.0
  Sympathoadrenergic overstimulation in Tako-Tsubo cardiomyopathy triggered by physical and emotional stress.
  Recommended by Brian Olshansky
  
• 3.0
  Trials and travails of electrogram-guided ablation of chronic atrial fibrillation.
  Recommended by Brian Olshansky
  
• 3.0
  The expectation effect and cardiac pacing for refractory vasovagal syncope.
  Recommended by Brian Olshansky
  
• 3.0
  Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.
  Recommended by Brian Olshansky
  
• 3.0
  A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
  Recommended by Brian Olshansky
  
• 3.2
  Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
  Recommended by Patrick Wouters, Brian Olshansky
  
• 3.0
  Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
  Recommended by Brian Olshansky
  
• 6.0
  Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope.
  Recommended by Brian Olshansky
  
• 6.0
  Arrhythmogenic right ventricular dysplasia: a United States experience.
  Recommended by Brian Olshansky